NCT06745882
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 28 words
- Trial sites expanded: 8 → 11 locations
- Collaborators: details revised at 1 of 3 entries
- Minor Study sites: 7 to 8v14
- Minor Study sites: 6 to 7v13
- Minor Study sites: 5 to 6v12
- Minor Study sites: 4 to 5v11
Show 7 earlier versionsHide 7 earlier versions
- Minor Study sites: 2 to 4v10
- Minor Study sites: 1 to 2v9
- Notable Start date: Jan 21, 2025 to Jun 13, 2025v8
- Minor Start date changed from estimate of Jan 2025 to Jan 21, 2025v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Notable Enrollment target: 24 to 318v3
- Notable Eligibility criteria shortened, about 412 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Non-interventional prospective cohort and participants will receive standard of care pembrolizumab with or without chemotherapy.
Cohort 2 Arm A will enroll patients with NSCLC with PD-L1 TPS status ≥1% and ctDNA tumor fraction low/negative and be treated with pembrolizumab monotherapy.
Cohort 2 Arm B will enroll patients with NSCLC with any PD-L1 status and ctDNAtumor fraction intermediate/high -OR- PD-L1 TPS\<1% and any ctDNA level treated with chemotherapy plus pembrolizumab.
Drugs: Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel
Sites
11 sites in 1 country